Published in Folia Neuropathol on January 01, 2008
The pathogenesis of Alzheimer's disease: a reevaluation of the "amyloid cascade hypothesis". Int J Alzheimers Dis (2011) 0.97
Cobalamin deficiency, hyperhomocysteinemia, and dementia. Neuropsychiatr Dis Treat (2010) 0.94
Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease. Metab Brain Dis (2012) 0.78
Hyperhomocysteinemia and homozygous MTHFR 677C>T mutation finding in an Alzheimer's disease case with metabolic syndrome diagnosis. Folia Neuropathol (2010) 0.75
Tritium-labeled (E,E)-2,5-bis(4'-hydroxy-3'-carboxystyryl)benzene as a probe for β-amyloid fibrils. Bioorg Med Chem Lett (2014) 0.75
Potential Links between Impaired One-Carbon Metabolism Due to Polymorphisms, Inadequate B-Vitamin Status, and the Development of Alzheimer's Disease. Nutrients (2016) 0.75
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J (2013) 2.15
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord (2008) 1.34
Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem (2004) 1.28
Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem (2008) 1.25
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol (2010) 1.21
Agraphia in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 with P301L MAPT mutation: dysexecutive, aphasic, apraxic or spatial phenomenon? Neurocase (2012) 1.12
Mitochondrial haplogroup H and Alzheimer's disease--is there a connection? Neurobiol Aging (2008) 1.07
Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord (2013) 1.07
Replication of BIN1 association with Alzheimer's disease and evaluation of genetic interactions. J Alzheimers Dis (2011) 1.07
GWAS risk factors in Parkinson's disease: LRRK2 coding variation and genetic interaction with PARK16. Am J Neurodegener Dis (2013) 1.03
Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. Mol Neurodegener (2012) 1.02
Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol Neurobiol (2012) 1.02
Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study. Mol Neurodegener (2011) 1.01
TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity. J Alzheimers Dis (2012) 0.97
Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol (2003) 0.97
Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment. Exp Neurol (2006) 0.97
Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol Neurobiol (2010) 0.96
Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson's disease risk in a Polish PD cohort. J Neural Transm (Vienna) (2008) 0.96
Insights into mitochondrial dysfunction: aging, amyloid-β, and tau-A deleterious trio. Antioxid Redox Signal (2012) 0.95
Role of nitric oxide in the brain during lipopolysaccharide-evoked systemic inflammation. J Neurosci Res (2007) 0.94
Alpha-synuclein potentiates Ca2+ influx through voltage-dependent Ca2+ channels. Neuroreport (2006) 0.93
Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics (2007) 0.92
VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep (2013) 0.91
Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: a study in stroke patients. Pharmacol Rep (2006) 0.91
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet (2012) 0.90
Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population. Neurosci Lett (2003) 0.90
Molecular mechanism of PC12 cell death evoked by sodium nitroprusside, a nitric oxide donor. Acta Biochim Pol (2008) 0.87
Polish Centenarians Programme. Multidisciplinary studies of successful ageing: aims, methods, and preliminary results. Exp Gerontol (2007) 0.87
Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry. Int J Geriatr Psychiatry (2013) 0.87
Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus. Brain Res (2010) 0.87
PIN1 gene variants in Alzheimer's disease. BMC Med Genet (2009) 0.86
Variation in NPC1, the gene encoding Niemann-Pick C1, a protein involved in intracellular cholesterol transport, is associated with Alzheimer disease and/or aging in the Polish population. Neurosci Lett (2008) 0.86
Alpha-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide. Neurochem Int (2006) 0.86
Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol Rep (2007) 0.86
Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Relat Disord (2011) 0.85
N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI). Med Sci Monit (2011) 0.85
Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors. Mol Neurobiol (2006) 0.85
Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther (2010) 0.85
Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease. PLoS One (2012) 0.85
Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett (2008) 0.85
Effect of poly(ADP-ribose) polymerase inhibitors on oxidative stress evoked hydroxyl radical level and macromolecules oxidation in cell free system of rat brain cortex. Neurosci Lett (2004) 0.84
A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene. PLoS One (2013) 0.84
Poly(ADP-ribose) polymerase during reperfusion after transient forebrain ischemia: its role in brain edema and cell death. J Mol Neurosci (2003) 0.84
Plasma homocysteine level and the course of ischemic stroke. Acta Neurobiol Exp (Wars) (2003) 0.84
Expression and activity of PARP family members in the hippocampus during systemic inflammation: their role in the regulation of prooxidative genes. Neurochem Int (2013) 0.84
Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells. Mol Neurobiol (2014) 0.83
Mutation screening of the MAPT and STH genes in Polish patients with clinically diagnosed frontotemporal dementia. Dement Geriatr Cogn Disord (2003) 0.83
Activation of constitutive nitric oxide synthase(s) and absence of inducible isoform in aged rat brain. Neurochem Int (2003) 0.83
Intra-familial clinical heterogeneity due to FTLD-U with TDP-43 proteinopathy caused by a novel deletion in progranulin gene (PGRN). J Alzheimers Dis (2010) 0.83
Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor. Folia Neuropathol (2009) 0.83
Earlier onset of Alzheimer's disease: risk polymorphisms within PRNP, PRND, CYP46, and APOE genes. J Alzheimers Dis (2009) 0.83
How community-dwelling seniors with multimorbidity conceive the concept of mental health and factors that may influence it: a phenomenographic study. Int J Qual Stud Health Well-being (2012) 0.82
Sigma receptor type 1 gene variation in a group of Polish patients with Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 0.82
Lipoxygenase inhibitors protect brain cortex macromolecules against oxidation evoked by nitrosative stress. Folia Neuropathol (2010) 0.82
alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochem Int (2008) 0.82
Analysis of UBQLN1 variants in a Polish Alzheimer's disease patient: control series. Dement Geriatr Cogn Disord (2008) 0.81
The use of MRI, CT and lumbar puncture in dementia diagnostics: data from the SveDem Registry. Dement Geriatr Cogn Disord (2014) 0.81
CYP46: a risk factor for Alzheimer's disease or a coincidence? Neurosci Lett (2005) 0.81
APP intracellular domain formation and unaltered signaling in the presence of familial Alzheimer's disease mutations. Exp Cell Res (2003) 0.81
Mitochondrial transcription factor A variants and the risk of Parkinson's disease. Neurosci Lett (2009) 0.81
Interleukin-6 gene (-174 C/G ) and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population. Neurol Neurochir Pol (2011) 0.81
Activated neutrophils oxidize extracellular proteins of endothelial cells in culture: effect of nitric oxide donors. Biochem J (2002) 0.81
The impact of mitochondrial and nuclear DNA variants on late-onset Alzheimer's disease risk. J Alzheimers Dis (2011) 0.80
Neurodegeneration, mitochondrial dysfunction, and oxidative stress. Oxid Med Cell Longev (2013) 0.80
Amyloid beta enhances cytosolic phospholipase A2 level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells. Acta Biochim Pol (2007) 0.80
Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem Int (2006) 0.80
Ultrastructural evidence of amyloid beta-induced autophagy in PC12 cells. Folia Neuropathol (2009) 0.80
ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener (2014) 0.80
Docosahexaenoic acid and tetracyclines as promising neuroprotective compounds with poly(ADP-ribose) polymerase inhibitory activities for oxidative/genotoxic stress treatment. Neurochem Int (2013) 0.80
The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study. J Alzheimers Dis (2013) 0.80
A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int (2010) 0.80
PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups. Parkinsonism Relat Disord (2012) 0.79
LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer's disease (LOAD). PLoS One (2013) 0.79
Cell cycle regulation distinguishes lymphocytes from sporadic and familial Alzheimer's disease patients. Neurobiol Aging (2010) 0.79
Identification of a late onset Alzheimer's disease candidate risk variant at 9q21.33 in Polish patients. J Alzheimers Dis (2012) 0.79
Prediction of deterioration of mild cognitive impairment with CT and SPECT. Med Sci Monit (2007) 0.79
Cognitive deficits and polymorphism of apolipoprotein E in Alzheimer's disease. Dement Geriatr Cogn Disord (2002) 0.79